title: How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: Can reduction of inflammation improve ESA dose response?
authors.affiliation: Division of Nephrology, Department of Medicine, University of Tennessee Health Science Center and Memphis VA Medical Center, Memphis, Tennessee.
authors.forename: Csaba P
authors.initials: CP
authors.lastname: Kovesdy
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000068256:Darbepoetin alfa; D004351:Drug Resistance / Q000502:physiology*; D004921:Erythropoietin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006397:Hematinics / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000503:physiopathology; D006435:Renal Dialysis; D051436:Renal Insufficiency, Chronic / Q000628:therapy*
chemical_list: D000893:Anti-Inflammatory Agents; D006397:Hematinics; D004921:Erythropoietin; D000068256:Darbepoetin alfa